Correlation Between BioInvent International and AstraZeneca PLC

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both BioInvent International and AstraZeneca PLC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BioInvent International and AstraZeneca PLC into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between BioInvent International AB and AstraZeneca PLC, you can compare the effects of market volatilities on BioInvent International and AstraZeneca PLC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BioInvent International with a short position of AstraZeneca PLC. Check out your portfolio center. Please also check ongoing floating volatility patterns of BioInvent International and AstraZeneca PLC.

Diversification Opportunities for BioInvent International and AstraZeneca PLC

-0.67
  Correlation Coefficient

Excellent diversification

The 3 months correlation between BioInvent and AstraZeneca is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding BioInvent International AB and AstraZeneca PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AstraZeneca PLC and BioInvent International is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BioInvent International AB are associated (or correlated) with AstraZeneca PLC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AstraZeneca PLC has no effect on the direction of BioInvent International i.e., BioInvent International and AstraZeneca PLC go up and down completely randomly.

Pair Corralation between BioInvent International and AstraZeneca PLC

Assuming the 90 days trading horizon BioInvent International AB is expected to generate 2.86 times more return on investment than AstraZeneca PLC. However, BioInvent International is 2.86 times more volatile than AstraZeneca PLC. It trades about 0.07 of its potential returns per unit of risk. AstraZeneca PLC is currently generating about -0.06 per unit of risk. If you would invest  3,345  in BioInvent International AB on September 3, 2024 and sell it today you would earn a total of  1,025  from holding BioInvent International AB or generate 30.64% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

BioInvent International AB  vs.  AstraZeneca PLC

 Performance 
       Timeline  
BioInvent International 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in BioInvent International AB are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, BioInvent International may actually be approaching a critical reversion point that can send shares even higher in January 2025.
AstraZeneca PLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days AstraZeneca PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

BioInvent International and AstraZeneca PLC Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with BioInvent International and AstraZeneca PLC

The main advantage of trading using opposite BioInvent International and AstraZeneca PLC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BioInvent International position performs unexpectedly, AstraZeneca PLC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will offset losses from the drop in AstraZeneca PLC's long position.
The idea behind BioInvent International AB and AstraZeneca PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Complementary Tools

Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance